Dr. Senthil Sukumar, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Kansas City, School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 96
Licensed in Texas since 2017, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Missouri, Kansas City, School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
TX license R5475 (first issued 2017; active) -
Hospitalist Physician
TX license R5475 (first issued 2017; active) -
Internal Medicine Physician
TX license R5475 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor St Lukes Medical Center Houston, TX
Medical groups
- Baylor College of Medicine (1,240 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 96
- Services billed
- 160
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 127 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 34 |
| New patient office or other outpatient visit, 45-59 minutes | 30 | 30 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Houston, TX | 43 |
| Hydroxyurea Other prescribers in Houston, TX | 30 |
| Xarelto (rivaroxaban) Other prescribers in Houston, TX | 18 |
| Droxia (hydroxyurea) Other prescribers in Houston, TX | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 12 payments worth $14,776 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $8,179 |
|---|---|
| Genzyme Corporation | $3,638 |
| Alexion Pharmaceuticals, Inc. | $2,959 |
| Consulting Fee | $13,516 |
|---|---|
| Travel and Lodging | $682 |
| Food and Beverage | $579 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 23, 2025 | Consulting Fee | $5,520 |
| Genzyme Corporation Apr 15, 2025 | Consulting Fee | $3,360 |
| Alexion Pharmaceuticals, Inc. Jul 4, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,945 |
| Novartis Pharmaceuticals Corporation Sep 18, 2025 | Consulting Fee | $1,691 |
| Novartis Pharmaceuticals Corporation Dec 23, 2025 | Travel and Lodging travel to East Hanover, NJ | $682 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $66,685 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
Novartis Pharmaceuticals Corporation - A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.